AZTA vs NEO: fair value comparison
Azenta, Inc. and NeoGenomics, Inc. · Updated 2026-10-19
NEO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, AZTA currently ranks higher by quality score.
| AZTA | NEO | |
|---|---|---|
| Verdict | Overvalued | Awaiting full valuation |
| Last price | $34.09 | $16.65 |
| 12-month range | $16.02–$42.73 | $7.19–$19.91 |
| Rank by discount to fair value | #107 of 108 Healthcare | — |
| Rank by quality score | #126 of 301 Healthcare | #128 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: AZTA fair value analysis · NEO fair value analysis